Intas has invested heavily in R & D and state-of-the-art manufacturing capabilities, in compliance with global standards and evolving formulations to meet the ever-growing demands of the competitive markets. Intas offers CRAMS Model (Contract Research and Manufacturing Services) to offshore clients from regulated and semi-regulated markets.

The capability to develop new formulations, the technology transfer and contract manufacturing of established products at committed costs, quality and time creates the competitive advantage for Intas. Moreover, the efficient and effective supply chain management and a strong regulatory knowledge base make it one of the most sought after companies by global clients.

Intas extends excellent contract manufacturing support to more than 50 clients for around 150 products in regulated markets comprising Europe, Australia, New Zealand, USA and Canada.

The company has a significant share in Contract Research and Manufacturing services in India and is making major headways with other global MNCs on this front. To fuel it further, Intas has forged alliances with major pharma giants.

Intas boasts of a state-of-the-art facility, duly approved by US FDA*, UK MHRA, Australia TGA, South Africa MCC and WHO-GMP in Ahmedabad. The facility includes Solid Oral manufacturing, Parenteral and Oncology Product manufacturing with capabilities to produce dosage forms in sterile and general, covering major therapeutic segments along with lyophilisation facility. The wide range of production techniques enables Intas to handle complex product packaging. There are two separate areas in Intas manufacturing site isolated by "Barrier Isolation". One is general area having dedicated manufacturing facility for Effervescent, Narrow Therapeutics and Pellets. The second is a facility for Cytotoxic and Potent dosage forms.
Annual capacities for various dosage forms are: